Catalyst Pharmaceuticals, Inc. (CPRX)
After hours:
| Previous Close | 14.72 |
| Open | 14.82 |
| Bid | 14.97 x 200 |
| Ask | 15.00 x 200 |
| Day's Range | 14.68 - 15.00 |
| 52 Week Range | 11.09 - 17.74 |
| Volume | |
| Avg. Volume | 1,342,085 |
| Market Cap | 1.769B |
| Beta (5Y Monthly) | 0.88 |
| PE Ratio (TTM) | 23.79 |
| EPS (TTM) | 0.63 |
| Earnings Date | May 08, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 26.71 |
ZacksCollegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksCatalyst Pharmaceutical (CPRX) Reports Next Week: Wall Street Expects Earnings Growth
Catalyst (CPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GlobeNewswireCatalyst Pharmaceuticals to Participate at the BofA Securities Health Care Conference 2024
CORAL GABLES, Fla., May 01, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases today announced that Richard J. Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will participate at the upcoming BofA Securities Health Care Conferen
